← Association for Accessible Medicines
FDANonrulemakingFDA-2015-N-3326

Biosimilar User Fee Act

RIN
—
Last modified
Jan 2, 2026
Comment window
closed 207d ago
Association for Accessible Medicines filings
3

Activity

Association for Accessible Medicines filed 3 comments on this docket between Dec 3, 2020 and Jan 2, 2026. 13 other organizations filed here. The comment window closed 207d ago.

What Association for Accessible Medicines filed (3)

Jan 2, 2026· Comment from Biosimilars Council, Association for Accessible Medicines (AAM)· FDA-2015-N-3326-0052

FDA, Please find attached comments from the Biosimilars Council regarding Docket No. FDA-2015-N-3326; "Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments." Thanks, Scott Kuzner, Ph.D., Senior Director, Sciences and Regulatory Affairs, on behalf of the Biosimilars Council, Association for Accessible Medicines (AAM) Biosimilars Council, Association for Accessible Medicines (AAM)

View on regulations.gov →
Nov 5, 2021· Comment from The Association for Accessible Medicines (AAM)· FDA-2015-N-3326-0040

Comments from the Association for Accessible Medicines (AAM) on the Reauthorization of the Biosimilar User Fee Act Public Meeting.

View on regulations.gov →
Dec 3, 2020· Comment from The Association for Accessible Medicines (AAM)· FDA-2015-N-3326-0031

Comments from The Association for Accessible Medicines (AAM) Biosimilar's Council on behalf of our member companies, regarding Reauthorization of the Biosimilar User Fee Act; Public Meeting.

View on regulations.gov →

Abstract

No abstract recorded.

View on regulations.gov →

Co-filers (13)

See everyone who commented →